Fotemustine
- Generic Name
- Fotemustine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H19ClN3O5P
- CAS Number
- 92118-27-9
- Unique Ingredient Identifier
- GQ7JL9P5I2
- Indication
原发性脑内肿瘤和播散性恶性黑色素瘤（包括脑内部位）。
- Associated Conditions
- Metastatic Melanoma
- Associated Therapies
- -
A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
Phase 3
- Conditions
- Brain Metastases
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Italian Network for Tumor Biotherapy Foundation
- Target Recruit Count
- 168
- Registration Number
- NCT02460068
- Locations
- 🇮🇹
S C Dermatology, A.O.U. City of Health and Science of Turin, Turin, Italy
🇮🇹Medical Oncology, Pope Giovanni XXIII Hospital, Bergamo, Italy
🇮🇹European Institute of Oncology, Milan, Italy
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT01474239
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
Phase 3
Completed
- Conditions
- Malignant MelanomaRecurrent Melanoma
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 269
- Registration Number
- NCT01359956
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01069627
Fotemustine in Treating Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Target Recruit Count
- 60
- Registration Number
- NCT00560118
- Locations
- 🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
Phase 3
Terminated
- Conditions
- Intraocular MelanomaMetastatic Cancer
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 171
- Registration Number
- NCT00110123
- Locations
- 🇮🇹
European Institute of Oncology, Milan, Italy
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
🇮🇹Azienda Ospedaliera di Padova, Padova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath